The Nasdaq Composite reached an all-time high on Friday, propelled by megacap tech stocks. The tech-heavy index increased by 0.56 per cent to close at 18,518.61, while the S&P 500 dipped 0.03 per cent to finish at 5,808.12. The Dow Jones Industrial Average fell by 259.96 points, or 0.61 per cent, ending the day at […]
Nasdaq hits record high as tech stocks surge Read More »
Jonathan Belz, CEO and Co-Founder of BFA Global Investors, presents at the Semiconductor Australia 2024 conference. Citing examples like Nvidia’s rapid market cap increase, Belz discusses how AI, 5G, and data centres are shaping a new era for the sector. Topics include:Investment insights: Belz shares insights from his 20-year career across Sydney, New York and
The digital economy’s oil: Jonathan Belz on semiconductor investment strategies Read More »
PYC Therapeutics (ASX:PYC) has announced significant progress in its efforts to develop RNA-based precision medicines for genetic diseases. The company is in the midst of clinical trials for its leading drug candidates targeting rare eye conditions, including Retinitis Pigmentosa type 11 (RP11) and Autosomal Dominant Optic Atrophy (ADOA). In a recent update, PYC reported positive
Positive trial results for PYC’s eye disease therapies Read More »
Judo Capital (ASX:JDO), an Australian bank specialising in lending to small and medium-sized enterprises (SMEs), has reported a solid year of financial performance, with a notable 9.5% increase in annual revenue for the fiscal year ending 30 June 2024. The bank’s revenue reached $326.6 million, driven by its focused lending strategy to underserved SMEs. Despite
Judo Capital reports increased revenue despite competition Read More »
Gold prices experienced notable fluctuations last week. Starting the week at US$2,722 per ounce on Monday, spot gold saw a rally in Asian and European sessions, reaching US$2,757.80, its all-time highest price, on Wednesday. It then encountered resistance from North American traders, dropping to US$2,710.90 on Thursday, as doubts over the precious metal’s short-term outlook emerged. This
Safe haven or risky bet? Gold struggles to find direction Read More »
CAR Group (ASX:CAR), a leader in online automotive marketplaces, has reported a robust first quarter for FY25, with a 41% increase in revenue compared to the previous year. This growth is largely attributed to the integration of key acquisitions, such as Trader Interactive in the US and Webmotors in Brazil, which have broadened CAR Group’s
CAR Group expands global reach with strategic acquisitions Read More »
Arovella Therapeutics (ASX:ALA) has recently released its quarterly report, announcing the receipt of a $3.0 million Research and Development (R&D) Tax Incentive refund, with an additional $0.3 million expected shortly. This funding enhances Arovella’s financial position as it advances its lead asset, ALA-101, towards first-in-human clinical trials. CEO Dr Michael Baker stated, “The R&D Tax
Arovella receives R&D tax incentive and new advisory board Read More »
Beach Energy (ASX:BPT) has successfully commenced gas production from its Thylacine West 1 and 2 development wells, which are now connected to the Otway Gas Plant. This milestone was achieved on 25 October 2024 and signifies a major advancement in the offshore drilling and development program within the Otway Basin. The Thylacine West development wells
Beach Energy achieves first gas production from Thylacine West Read More »
Whitehaven Coal (ASX:WHC) has reported a robust start to FY25, driven by gains in its Queensland operations. The company’s September quarter saw a managed run-of-mine (ROM) production of 9.7 million tonnes (Mt), consistent with the previous June quarter. Queensland operations contributed significantly, with ROM production up 11% from June, reaching 5.3Mt. This improvement was attributed
Whitehaven’s Queensland mines shine amid Q1 FY25 results Read More »
ResMed (ASX:RMD), a global leader in sleep and respiratory care, reported strong results for the first quarter of FY25, with revenue climbing 11% year-over-year to $1.2bn. This growth was driven by robust sales of sleep apnoea devices and a growing presence in the digital health sector. Gross margins improved to 58.6%, as operational efficiencies and
ResMed posts double-digit revenue growth driven by sleep device sales Read More »
